OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 3.

Table. 3.

Factors associated with the hospitalization during symptomatic breakthrough infection after a third vaccination dose

Variables BI needing hospitalization (N=12) BI without hospitalization (N=52) Univariable Multivariable*
HR 95% CI P HR 95% CI P
Age, mean±SD, yrs 49.7±18.0 48.3±13.6 1.01 0.96–1.06 0.766
Male sex, N (%) 8 (66.7) 26 (50.0) 2.00 0.56–8.26 0.303 5.42 0.71–41.37 0.103
Body mass index, mean±SD, kg/m2 21.4±2.5 23.6±3.8 0.83 0.67–1.00 0.070 0.71 0.50–1.01 0.056
Dialysis duration, median (IQR), month 50.5 (7.2–76.3) 5.8 (0–29.5) 1.01 1.00–1.03 0.057
Time from third dose to infection, mean±SD, days 62.8±33.9 85.4±24.9 0.97 0.95–0.99 0.017 0.97 0.94–1.00 0.076
Post-third dose anti-spike IgG titer <200 AU/mL, N (%) 11 (91.7) 20 (38.5) 17.6 3.07–334.00 0.008 36.38 2.69–492.60 0.007

*The multivariable logistic regression model included sex, age, and factors with P≤0.2 in univariable tests (i.e., body mass index, dialysis duration, platelet count, Hb level, time from booster vaccination to infection, and post-booster anti-RBD IgG titer <200 AU/mL).

Post-booster anti-RBD IgG titer was <200 AU/mL.

Abbreviations: BI, breakthrough infection; IQR, interquartile range; RBD, receptor-binding domain.

© Ann Lab Med